Over the years we have been characterizing mice with different Akt isoforms deficiencies for survival, lifespan, and susceptibility to cancer. The current renewal application is focused on new and unexpected observations made during the last funding period. These observations are: (i) Systemic whole body deletion of Akt1 in adult mice inhibits tumor progression in a mouse cancer model that is not driven by Akt activation. (ii) The deletion of either Akt1 or Akt2 does not inhibit liver carcinogenesis, and Akt2 deletion increases lung metastasis induced by liver carcinogenesis. (iii) The deletion of both Akt1 and Akt2 in the liver induces spontaneous hepatocellular carcinoma (HCC). (iv) Germ line deletion of Akt1 and Akt3 causes embryonic lethality, but the systemic deletion of Akt1 and Akt3 in adult mice is well tolerated. (v) The deletion of Akt1 increases the lifespan of mice. (iv) The systemic deletion of Akt1 and Akt2 in adult mice induces rapid mortality. These findings suggest that drugs, which target predominately Akt1 and not Akt2 could be effective and well tolerated in cancer therapy. By contrast, drugs that effectively inhibit both Akt1 and Akt2 could be deleterious and pro-liver carcinogenesis. Since Akt activation is perhaps the most frequently event occurring in human cancers, and targeting Akt activation for cancer therapy is in progress, our studies should have a profound impact on cancer therapy. The overall goal of this project is to determine the physiological consequences of Akt deletion in the mouse and their underlying mechanisms with implications to cancer therapy.

Public Health Relevance

Akt activation is perhaps the most frequently event occurring in human cancers, and targeting Akt activation for cancer therapy is in progress, our studies should have a profound impact on cancer therapy. Our findings suggest that drugs, which target predominately Akt1 and not Akt2 could be effective and well tolerated in cancer therapy. By contrast, drugs that effectively inhibit both Akt1 and Akt2 could be deleterious and pro-liver carcinogenesis. The overall goal of this project is to determine the physiological consequences of Akt deletion in the mouse and their underlying mechanisms with implications to cancer therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
2R01AG016927-16
Application #
8637580
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Finkelstein, David B
Project Start
1998-09-01
Project End
2019-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
16
Fiscal Year
2014
Total Cost
$405,451
Indirect Cost
$151,250
Name
University of Illinois at Chicago
Department
Biochemistry
Type
Schools of Medicine
DUNS #
098987217
City
Chicago
State
IL
Country
United States
Zip Code
60612
Guzman, Grace; Chennuri, Rohini; Chan, Alexander et al. (2015) Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma. Dig Dis Sci 60:420-6
Li, Jing; Kim, Kyungho; Hahm, Eunsil et al. (2014) Neutrophil AKT2 regulates heterotypic cell-cell interactions during vascular inflammation. J Clin Invest 124:1483-96
Patra, Krushna C; Hay, Nissim (2014) The pentose phosphate pathway and cancer. Trends Biochem Sci 39:347-54
Nogueira, Veronique; Hay, Nissim (2013) Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clin Cancer Res 19:4309-14
Patra, Krushna C; Wang, Qi; Bhaskar, Prashanth T et al. (2013) Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24:213-28
Halasi, Marianna; Wang, Ming; Chavan, Tanmay S et al. (2013) ROS inhibitor N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors. Biochem J 454:201-8
Xu, P-Z; Chen, M-L; Jeon, S-M et al. (2012) The effect Akt2 deletion on tumor development in Pten(+/-) mice. Oncogene 31:518-26
Nogueira, Veronique; Sundararajan, Deepa; Kwan, Jennifer M et al. (2012) Akt-dependent Skp2 mRNA translation is required for exiting contact inhibition, oncogenesis, and adipogenesis. EMBO J 31:1134-46
O'Brien, Kelly A; Stojanovic-Terpo, Aleksandra; Hay, Nissim et al. (2011) An important role for Akt3 in platelet activation and thrombosis. Blood 118:4215-23
Park, Hyun Jung; Gusarova, Galina; Wang, Zebin et al. (2011) Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol Med 3:21-34

Showing the most recent 10 out of 33 publications